BioNexus Gene Lab Corp Files Definitive Proxy Statement

TL;DR

BioNexus Gene Lab Corp filed its DEF 14A. Standard proxy stuff for shareholders.

AI Summary

BioNexus Gene Lab Corp. filed a Definitive Proxy Statement (DEF 14A) on September 16, 2024, for the fiscal year ending December 31, 2024. The company, incorporated in Wyoming, is based in Kuala Lumpur and operates in the medical laboratories sector. This filing is a standard procedural document related to shareholder meetings and corporate governance.

Why It Matters

This filing provides shareholders with essential information regarding upcoming meetings, voting procedures, and corporate governance matters, allowing them to make informed decisions.

Risk Assessment

Risk Level: low — This is a routine DEF 14A filing, which is a standard disclosure document for public companies and does not inherently indicate new risks.

Key Players & Entities

• BioNexus Gene Lab Corp (company) — Registrant
• 0001477932-24-005760 (filing_id) — Accession Number
• 20240916 (date) — Filing Date
• 20241004 (date) — Period of Report
• 0001737523 (company_id) — Central Index Key
• 8071 (sic_code) — Standard Industrial Classification
• WY (state) — State of Incorporation
• 1231 (date) — Fiscal Year End
• 001-41750 (filing_number) — SEC File Number
• Kuala Lumpur (location) — Business Address City

FAQ

Filing Documents

• bglc_def14a.htm (DEF 14A) — 536KB
• 0001477932-24-005760.txt ( ) — 537KB

Executive Compensation

Executive Compensation 30

Security Ownership Of Certain Beneficial Owners And Management

Security Ownership Of Certain Beneficial Owners And Management 33 Householding of Proxy Materials 34 Other Matters 34 Where You Can Find Additional Information 34 2024 Stock Incentive Plan Annex A A-1 Form of Reverse Stock Split Charter Amendment Annex B B-1

Forward-Looking Statements

Forward-Looking Statements This proxy statement (this "Proxy Statement") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Proxy Statement that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company's intent or ability to effect a reverse stock split or to regain compliance with any applicable Nasdaq listing requirements. These statements are based on management's current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including that the stock incentive plan contemplated in proposal 3 and the reverse stock split contemplated in Proposal 4 (the "Reverse Stock Split") may not be approved by the Company's stockholders. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Proxy Statement, please see the risks and uncertainties identified under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, which is available on the Company's Investor Relations website at http://www.bionexusgenelab.com and on the SEC website at www.sec.gov . All forward-looking statements reflect the Company's beliefs and assumptions only as of the date of this Proxy Statement. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances. Capitalized terms shall have the meanings ascribed to such terms in the Proxy Statement. 2 Table of Contents BIONEXUS GENE LAB CORP. PROXY STATEMENT ANNUAL MEETING OF STOCKHOLDERS To Be Held On October

View Full Filing

View this DEF 14A filing on SEC EDGAR